Beranda › Kanker Paru Non-Sel Kecil › Indiana › Indianapolis
Uji klinis Kanker Paru Non-Sel Kecil di Indianapolis, IN
32 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Indianapolis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Menerima pesertaFase 3
- Saint Catherine Hospital, Indianapolis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Saint Catherine Hospital, Indianapolis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- IU Simon Cancer Center, Indianapolis
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Menerima pesertaFase 3
- Franciscan Health ( Site 0219), Indianapolis
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #4, Indianapolis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- IU Health West Hospital, Avon · 13 mi jauhnya
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Franciscan Health, Indianapolis
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Menerima pesertaFase 2/3
- Indiana University Health University Hospital, Indianapolis
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Menerima pesertaFase 1/2
- Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Community Health Network, Indianapolis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Site, Indianapolis
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Menerima pesertaFase 1
- Community Health Network, Indianapolis
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Community Health Network, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- dan 1 lainnya
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Menerima pesertaFase 3
- Franciscan Health Indianapolis, Indianapolis
A Study of LY4175408 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Community Health Network, Indianapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Menerima pesertaFase 1
- Community Health Network, Inc. /ID# 243011, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Menerima pesertaFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
A Study of VET3-TGI in Patients With Solid Tumors
Menerima pesertaFase 1
- Community Health Network, Indianapolis
Repositioning Immunotherapy in VetArans With Lung Cancer
Menerima pesertaFase 2
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Menerima pesertaFase 1/2
- Research Site, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Menerima peserta
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
Menerima pesertaStudi observasional
- Community Health Network, Indianapolis
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Menerima peserta
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Menerima pesertaFase 1/2
- Community Health Network, Inc., Indianapolis
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Indianapolis
- Kanker (semua jenis)24 studi
- Gagal Jantung23 studi
- Obesitas20 studi
- Kanker Payudara20 studi
- Kanker Metastatik19 studi
- Kanker Kolorektal18 studi
- Kanker Ovarium17 studi
- Penyakit Kardiovaskular17 studi
- Kanker Paru16 studi
- Diabetes Tipe 114 studi
- Kanker Endometrium14 studi
- Penyakit Alzheimer14 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.